1 October 1999 in American Journal of Respiratory and Critical Care Medicine
In previous analyses of the occurrence of central (CSA) and obstructive sleep apnea (OSA) in patients with congestive heart failure (CHF), only men were studied and risk factors for these disorders were not well characterized. We therefore analyzed risk factors for CSA and OSA in 450 consecutive patients with CHF (382 male, 68 female) referred to our sleep laboratory. Risk factors for CSA were male gender (odds ratio [OR] 3.50; 95% confidence interval [CI], 1.39 to 8.84), atrial fibrillation (OR 4.13; 95% CI 1.53 to 11.14), age > 60 yr (OR 2.37; 95% CI 1.35 to 4.15), and hypocapnia (Pco2< 38 mm Hg during wakefulness) (OR 4.33; 95% CI 2.50 to 7.52). Risk factors for OSA differed by gender: in men, only body mass index (BMI) was significantly associated with OSA (OR for a BMI > 35 kg/m2, 6.10; 95% CI 2.86 to 13.00); whereas, in women, age was the only important risk factor (OR for age > 60 yr, 6.04; 95% CI 1.75 to 20.0). We conclude that historical information, supplemented by a few simple laboratory tests may enable physicians to risk stratify CHF patients for the presence of CSA or OSA, and the need for diagnostic polysomnography for such patients. Sin DD, Fitzgerald F, Parker JD, Newton G, Floras JS, Bradley TD. Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure.
1 September 2004 in The Lancet
18 September 2006 in Archives of internal medicine (1960)
Research from JAMA Internal Medicine — Sleepiness and Sleep in Patients With Both Systolic Heart Failure and Obstructive Sleep Apnea
12 September 2006 in Circulation
19 February 1998 in New England Journal of Medicine
The organic nitrates are widely used in the management of coronary artery disease. They are given not only to patients with stable angina pectoris, but also to those with unstable angina, acute myocardial infarction, and heart failure. Although they are effective for the treatment of these disorders, their therapeutic value is compromised by the rapid development of tolerance during sustained therapy. This review will be limited to the use of organic nitrates in patients with chronic stable angina pectoris, but many of the principles enunciated are relevant to other clinical situations.In 1879 Murrell reported that a 1 percent solution . . .